Table 1 |
||||
|
Summary of results with 95% bias-corrected bootstrap confidence intervals |
||||
| With supposed higher background incidence due to increased hormone therapy use (+21%) |
Combined estimate (50 to 69 years) with non-adjusted background incidence |
|||
|
|
||||
| Women aged 50 to 59 years |
Women aged 60 to 69 years |
Combined estimate (50 to 69 years) |
||
|
|
||||
| Time taken from 10 mm to 20 mm (years) |
||||
| Mean |
1.4 (1.1, 1.5) |
2.1 (1.8, 2.4) |
1.7 (1.5, 1.8) |
2.0 (1.8, 2.2) |
| Standard deviation |
1.9 (1.7, 2.2) |
2.4 (2.1, 2.7) |
2.2 (2.0, 2.4) |
2.7 (2.5, 2.9) |
| Volume doubling time at 15 mm (days) |
||||
| 25th percentile |
29 (19, 36) |
65 (47, 79) |
41 (32, 48) |
29 (21, 35) |
| 50th percentile |
73 (56, 86) |
143 (116, 165) |
99 (84, 111) |
94 (77, 107) |
| 75th percentile |
180 (148, 205) |
308 (253, 352) |
234 (204, 259) |
287 (243, 322) |
| Screening test sensitivity |
||||
| 5 mm |
29 (21, 36) |
24 (18, 30) |
26 (22, 31) |
26 (22, 31) |
| 10 mm |
92 (88, 99) |
91 (86, 98) |
91 (88, 96) |
91 (87, 96) |
| Indicators of potential screening efficacy |
||||
| Mean sojourn time (years) |
2.3 (2.0, 2.6) |
3.5 (3.1, 3.9) |
2.8 (2.6, 3.1) |
3.4 (3.1, 3.6) |
| Proportion of tumors visible on screening |
0.95 (0.94, 0.96) |
0.95 (0.95, 0.96) |
0.95 (0.95, 0.96) |
0.95 (0.95, 0.96) |
|
|
||||
|
Weedon-Fekjær et al. Breast Cancer Research 2008 10:R41 doi:10.1186/bcr2092 |
||||
